The Michael J. Fox Foundation for Parkinson’s Research (MJFF) launched its landmark study, the Parkinson’s Progression Markers Initiative (PPMI), in 2010 to better understand Parkinson’s disease (PD) and advance new treatments. Since then, the study has changed how research is done and what scientists know about the brain. It is a cornerstone of our understanding of disease and has heavily influenced clinical trials.
Today, PPMI is entering its most ambitious era yet and growing its in-clinic study recruitment from 1,400 to 4,000 volunteers across nearly 50 clinical sites in 12 countries by year-end 2023. Participants contribute biological samples and undergo assessments to characterize Parkinson’s risk, onset and progression.
We are currently screening new potential volunteers:
• People diagnosed with Parkinson’s in the past two years and who are not yet taking medication
• People age 60 and older who do not have Parkinson’s, but are living with certain risk factors, including:
 A parent, sister, brother or child with Parkinson’s
 A genetic mutation linked to Parkinson’s (GBA, LRRK2, SNCA, PRKN, PINK1)
 Acting out dreams while asleep (REM sleep behavior disorder)

• People with no known connection to Parkinson’s who wish to participate as control volunteers

Volunteers in Canada interested in enrolling can contact our research coordinators based on their closest location (To get started, contact study staff below).

Contact information

Name: Danica Nogo
Phone: 416-603-5800 ext 3415

Toronto, ON- Toronto Western Hospital

Name: Shawna Reddie

Ottawa, ON- The Ottawa Hospital 

Share this: